Yelena Y. Janjigian, MD

Yelena Y. Janjigian, MD, is chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center.

Articles

Dr Janjigian on the Efficacy of Durvalumab Plus Chemotherapy in Resectable GEJ Adenocarcinoma

June 24th 2025

Yelena Y. Janjigian, MD, discussed results from the MATTERHORN study of durvalumab plus FLOT in resectable gastric/gastroesophageal junction cancer.

Event-free Survival (EFS) in MATTERHORN: A Randomized, Phase 3 Study of Durvalumab plus 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel Chemotherapy (FLOT) in Resectable Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

June 23rd 2025

Presented by Yelena Y. Janjigian at ASCO 2025, the Phase 3 MATTERHORN study demonstrated that adding durvalumab to FLOT significantly improved event-free survival compared with FLOT alone in patients with resectable gastric and gastroesophageal junction adenocarcinoma, with consistent benefit across subgroups and no new safety concerns.

GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting

June 19th 2025

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Dr Janjigian on Safety Considerations With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer

May 19th 2025

Yelena Y. Janjigian, MD, discusses the safety of nivolumab plus chemotherapy for the first-line treatment of patients with gastric/GEJ/esophageal cancer.

Dr Janjigian on Future Research Directions for Immunotherapy in Gastric/GEJ/Esophageal Cancer

May 15th 2025

Yelena Y. Janjigian, MD, discusses future research directions with nivolumab-based treatments in gastric, GEJ, and esophageal cancer.

Dr Janjigian on 5-Year Data With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer

February 24th 2025

Yelena Y. Janjigian, MD, discusses 5-year follow-up findings for nivolumab plus chemotherapy vs chemotherapy alone in gastric/GEJ adenocarcinoma.

Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma

November 22nd 2024

Yelena Y. Janjigian, MD, discusses the significance of the FDA approval of zolbetuximab plus chemotherapy for HER2–, CLDN18.2+ gastric/GEJ adenocarcinoma.

Dr Janjigian on Final OS Results With Pembrolizumab Plus Trastuzumab and Chemo in HER2+ Gastric/GEJ Cancer

October 7th 2024

Yelena Y. Janjigian, MD, discusses final overall survival data from the phase 3 KEYNOTE-811 trial in HER2-positive metastatic gastric or GEJ adenocarcinoma.

Nivolumab Plus Chemotherapy vs Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: 4-Year Follow-Up of the CheckMate 649 Study

January 30th 2024

Yelena Y. Janjigian, MD, presents 4-year follow-up data from the CheckMate 649 study investigating frontline nivolumab plus chemotherapy in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

Dr Janjigian on Pembrolizumab/Trastuzumab/Chemotherapy in HER2+ Gastric Cancer

October 28th 2023

Yelena Y. Janjigian, MD, discusses results from the primary progression-free survival and interim overall survival analyses of the phase 3 KEYNOTE-811 trial in patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma, and contextualizes these findings with previously reported data from this trial.

Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian

October 24th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Nivolumab plus chemotherapy vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: 3-year follow-up from CheckMate 649

February 10th 2023

Yelena Y. Janjigian, MD, reviews the 3-year follow-up data from the CheckMate 649 trial investigating nivolumab plus chemotherapy as a first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

Gathering Insights in Gynecologic, Lung, and GI Cancers From ESMO 2022: Drs Matulonis, Peters, and Janjigian

September 11th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr. Janjigian on the FDA Approval of Nivolumab Plus Chemotherapy in Frontline Gastric Cancer

May 11th 2021

Yelena Y. Janjigian, MD, discusses the FDA approval of nivolumab plus chemotherapy in frontline gastric cancer.

Dr. Janjigian on the Importance of Routine HER2 Testing in Gastric/GEJ Cancer

January 13th 2021

Yelena Y. Janjigian, MD, discusses the importance of routine HER2 testing in gastric/gastroesophageal cancer.

Dr. Janjigian on the Expanding Treatment Armamentarium in HER2+ Gastric Cancer

January 7th 2021

Yelena Y. Janjigian, MD, discusses the expanding treatment armamentarium in HER2-positive gastric cancer.

Dr. Janjigian on the Emergence of New Treatment Options in Esophageal and Gastric Cancer

December 11th 2020

Yelena Y. Janjigian, MD, discusses the emergence of new treatment options in esophageal and gastric cancer.

Dr. Janjigian on the Importance of First-Line Therapy Selection in Gastric Cancer

November 24th 2020

Yelena Y. Janjigian, MD, discusses the importance of selecting ​an optimal first-line therap​y in gastric cancer.

Dr. Janjigian on the Importance of Biomarker Testing in GI Cancers

November 19th 2020

Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of biomarker testing in gastrointestinal cancers.

Dr. Janjigian on Updated Results from the DESTINY-Gastric01 Trial in HER2+ Gastric Cancer

June 25th 2020

Yelena Y. Janjigian, MD, discusses updated results from the ​phase 2 DESTINY-Gastric01 trial​ in previously treated patients with HER2-positive gastric cancer.

x